Designing Innovative Non-Systemic Protein Therapeutics to Make a Difference for Cystic Fibrosis Patients

Alnara Pharmaceuticals is a biopharmaceutical company dedicated to developing novel protein therapeutics for the treatment of metabolic diseases. The company’s innovative approach focuses on designing effective protein therapies that can be orally delivered directly to the gastrointestinal tract without being absorbed into the bloodstream. Alnara was acquired by Eli Lilly and Company in 2010.

Year Invested: 2008

Associated Team Members

Robert Tepper, M.D.